Last reviewed · How we verify
Single intravenous injection of Tegileridine Fumarate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Single intravenous injection of Tegileridine Fumarate (Single intravenous injection of Tegileridine Fumarate) — Second Affiliated Hospital, School of Medicine, Zhejiang University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Single intravenous injection of Tegileridine Fumarate TARGET | Single intravenous injection of Tegileridine Fumarate | Second Affiliated Hospital, School of Medicine, Zhejiang University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Single intravenous injection of Tegileridine Fumarate CI watch — RSS
- Single intravenous injection of Tegileridine Fumarate CI watch — Atom
- Single intravenous injection of Tegileridine Fumarate CI watch — JSON
- Single intravenous injection of Tegileridine Fumarate alone — RSS
Cite this brief
Drug Landscape (2026). Single intravenous injection of Tegileridine Fumarate — Competitive Intelligence Brief. https://druglandscape.com/ci/single-intravenous-injection-of-tegileridine-fumarate. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab